Raghad O. Alharbi

Raghad O. Alharbi

Auto-generated profile, based on publicly available information

Raghad O. Alharbi

Department of Internal Medicine College of Medicine King Saud bin Abdulaziz University for Health Sciences Riyadh Saudi Arabia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2026 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
SAShahad J AlShammary
Shahad J AlShammary
NANasser Eid Alotaibi
Nasser Eid Alotaibi
RARaghad Alharbi
Raghad Alharbi
RARuba M AlJohani
Ruba M AlJohani
BABader Alotaibi
Bader Alotaibi
SISamah Ibrahim
Samah Ibrahim
Introduction: Although catheter ablation is a cornerstone in arrhythmia management, hospital readmissions, emergency room (ER) visits, and complications remain a significant clinical burden. Defining their frequency and predictors is essential to optimize patient follow-up and outcomes after ablation. Methods: To evaluate the rates and predictors of 90-day hospital readmissions and emergency room visits following catheter ablation, as well as procedure-related complications, among patients undergoing catheter ablation, a retrospective cohort study was conducted at King Abdulaziz Cardiac Center (Riyadh, Saudi Arabia), including adult patients undergoing catheter ablation between June 2022 and June 2024. Data were extracted from BestCare electronic medical records and analyzed using Fisher’s exact tests and logistic regression. Results: Among 176 patients, 13 (7.4%) were readmitted and 23 (13.1%) visited the ER, predominantly due to arrhythmia recurrence (61.5% and 60.9%, respectively). Recurrent events occurred in a subset of patients and were significantly more frequent among older individuals and those with a higher comorbidity burden (p< 0.01). Conclusion: Ninety-day readmissions and ER visits after catheter ablation were infrequent, mostly due to arrhythmia recurrence. Independent predictors included older age and comorbidity burden, underscoring the need for risk stratification and structured follow-up strategies to reduce preventable healthcare utilization.

23 September 2025 in Journal of the Saudi Heart Association
Verified
Journal Article
Open access
PDF file
RARaghad O. Alharbi
Raghad O. Alharbi
SAShahad J. AlShammary
Shahad J. AlShammary
NANasser Eid Alotaibi
Nasser Eid Alotaibi
RARuba M. Aljohani
Ruba M. Aljohani
BABader A. Alotaibi
Bader A. Alotaibi
ISIhab F. Suliman
Ihab F. Suliman
Lung cancer is among the most diagnosed cancers worldwide, and its co-occurrence with coronary heart disease is life-threatening. Osimertinib is the standard treatment for epidermal growth factor receptor (EGFR) mutations in advanced non-small cell lung cancer (NSCLC). The addition of pemetrexed and carboplatin increases not only the efficacy but also the cardiotoxicity risk. We report a 59-year-old woman with NSCLC alongside brain, liver, and spleen metastases, who developed cardiovascular events following cancer therapy. With advanced imaging and multidisciplinary intervention, remarkable remission was achieved over two years. Reporting this case contributes to the understanding of its presentation and diagnostic challenges.